2 June 2021
Diurnal Group plc
("Diurnal" or the "Company")
Director Dealings
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces the following Directors' dealings:
Richard Ross, Chief Scientific Officer transferred 36,738 Ordinary Shares for nil consideration to a non-dependent child. Following the transaction, the total beneficial interest of Richard Ross and his wife is 2,184,355 Ordinary Shares, representing 1.3% of the total voting rights as at 2 June 2021.
Details of the full notifications received by the Company are set out below:
| 1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
| a)
| Name
| Richard Ross | |||
| 2
| Reason for the notification
| ||||
| a)
| Position/status
| Chief Scientific Officer | |||
| b)
| Initial notification /Amendment
| Initial notification | |||
| 3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
| a)
| Name
| Diurnal Group plc | |||
| b)
| LEI
| 213800I2HNUNZN1LDH29 | |||
| 4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
| a)
| Description of the financial instrument, type of instrument | Ordinary shares of 5 pence each in Diurnal Group plc | |||
| | | ||||
| Identification code | GB00BDB6Q760 | ||||
| | | ||||
| b)
| Nature of the transaction
| Transfer of ordinary shares
| |||
| c)
| Price(s) and volume(s) | | | | |
| | | Price(s) | Volume(s) | | |
| | | Nil consideration | 36,738 |
| |
| | | | | | |
| d)
| Aggregated information | | |||
| | | ||||
| - Aggregated volume | As above | ||||
| | | ||||
| - Price | | ||||
| | | ||||
| e)
| Date of the transaction
| 1 June 2021 | |||
| f)
| Place of the transaction
| XLON | |||
| For further information, please visit www.diurnal.co.uk or contact: | |
| | |
| Diurnal Group plc | +44 (0)20 3727 1000 |
| Martin Whitaker, Chief Executive Officer | |
| Richard Bungay, Chief Financial Officer | |
| | |
| Panmure Gordon (UK) Limited (Nominated Adviser and Sole Broker) | +44 (0)20 7886 2500 |
| Corporate Finance: Freddy Crossley, Emma Earl | |
| Corporate Broking: Rupert Dearden | |
| | |
| FTI Consulting (Media and Investor Relations) | +44 (0)20 3727 1000 |
| Simon Conway | |
| Victoria Foster Mitchell | |
| Alex Davis | |
Notes to Editors
About Diurnal Group plc
Diurnal Group plc is a European, UK-headquartered, specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism and hypothyroidism. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.
For further information about Diurnal, please visit www.diurnal.co.uk
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
